Silexion Therapeutics Corp - 10-Q Filing
Silexion Therapeutics Corp filed its quarterly report for March 31, 2026, disclosing financial results including $1.2 million outstanding under a promissory note with Moringa Sponsor L.P., and outlining expenses related to research and development as well as general administrative costs.
Tickers: $SLXN